key: cord-1014317-yxqkh120
authors: Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Khan, Muhammad Shahzeb; Ahmed, Areeba; Ali, Syed Saad; Michos, Erin D.; Hall, Michael E.; Krasuski, Richard A.; Greene, Stephen J.; Butler, Javed; Alkhouli, Mohamad
title: A Meta-Analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
date: 2020-06-02
journal: Am J Cardiol
DOI: 10.1016/j.amjcard.2020.05.038
sha: da42a313c6e60aade1b93a51a154694b11185323
doc_id: 1014317
cord_uid: yxqkh120

nan

The angiotensin converting enzyme (ACE) 2 is a cell surface protein used for entry into type II pneumocytes and other tissues by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -the infective agent of COVID-19.(1) It has been demonstrated that ACE2 is upregulated on tissues by renin-angiotensin-aldosterone (RAAS) inhibitors. This raised concerns that RAAS inhibitors may increase susceptibility and worsen prognosis in COVID-19. On the other hand, ACE2 facilitates degradation of angiotensin II and has an anti-inflammatory function and may actually protect the lungs and other tissues from injury.(1) Thus, the effect of RAAS inhibitors on susceptibility and prognosis of COVID-19 continues to be the subject of much debate.(1) Individual observational studies in the area have yielded equivocal results; hence, we sought to conduct a meta-analysis of all available data to provide greater insight.

For this study, PubMed and Scopus were searched in May 2020 using the following keywords and their MeSH terms: 'COVID-19', 'hypertension', 'ACE inhibitors (ACEIs)', and 'Angiotensin receptor blockers (ARBs)'. Studies were included if they: (1) they reported the risk of testing positive for COVID-19 and/or the risk of mortality in COVID-positive patients; and (2) compared hypertensive patients prescribed RAAS inhibitors to those not using these drugs. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) from each study were pooled using a random-effects model. A p-value <0.05 was considered significant.

Our initial search yielded 950 potential studies. After exclusions, nine studies(2-10) with a total of 80,526 patients (n= 21,642 ACEI/ARB users and n=58,884 non-users) remained for analysis. Study and baseline characteristics are provided in Table 1 . Pooled analysis revealed no p=0.90; I2=5%) ( Figure 1B) . Similarly, no significant difference was observed in mortality rate among hypertensive patients prescribed RAAS inhibitors compared to hypertensive patients did not prescribe these medications (OR: 0.57 [0.20-1.33]; p=0.25; I2=86%) ( Figure 1C) .

The results of the current meta-analysis suggest that neither ACEI nor ARB use is significantly associated with the odds of testing positive with COVID-19. This result can be considered robust, as it was derived from 3 large-scale studies (2, 4, 7) which adjusted for multiple potential confounding factors, including age, sex and comorbidities. Our findings also show no significant association between RAAS inhibitor use and mortality in COVID-19 patients; however, this result must be viewed with caution as -due to the lack of data -we were unable to analyze ACEI users and ARB users separately, and adjusted data was reported by only one study. In this context, specific aspects of our analysis are notable. COVID-19 patients using RAAS inhibitors are older and have a higher burden of comorbidities, and this may have 8

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Association of Use of

Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

System Inhibitors and Risk of Covid-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19